Skip to main content

Table 2 Objective response in 41 patients

From: Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Responses No. of patients %
Complete response 2 5
Partial response 13 32
Stable disease 17 41
Progressive disease 9 22
Clinical Benefit 32 78